会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Method of manufacturing copper electrode
    • 铜电极的制造方法
    • US08647815B1
    • 2014-02-11
    • US13558912
    • 2012-07-26
    • Masakatsu KurokiTakeshi Kono
    • Masakatsu KurokiTakeshi Kono
    • G03F7/26
    • C23C18/1216
    • A method for manufacturing an electrode comprising the steps of: applying onto a substrate a conductive paste to form a conductive paste layer comprising; (i) 100 parts by weight of a copper powder coated with a metal oxide selected from the group consisting of silicon oxide (SiO2), zinc oxide (ZnO), aluminum oxide (Al2O3), titanium oxide (TiO2), magnesium oxide (MgO) and a mixture thereof; (ii) 5 to 30 parts by weight of a boron powder; and (iii) 0.1 to 10 parts by weight of a glass frit; dispersed in (iv) an organic vehicle; and firing the conductive paste in air.
    • 一种用于制造电极的方法,包括以下步骤:在基底上施加导电膏以形成导电浆料层,其包括: (i)100重量份涂覆有选自氧化硅(SiO 2),氧化锌(ZnO),氧化铝(Al 2 O 3),氧化钛(TiO 2),氧化镁(MgO) )及其混合物; (ii)5〜30重量份的硼粉末; 和(iii)0.1至10重量份的玻璃料; 分散在(iv)有机载体中; 并在空气中烧制导电膏。
    • 4. 发明申请
    • 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS
    • 4-二甲基苯胺基 - 取代的萘啶,并作为药物使用
    • US20110263549A1
    • 2011-10-27
    • US13057330
    • 2009-07-23
    • Dennis FiegenSandra HandschuhSilke HobbieMatthias HoffmannTakeshi KonoYayoi SatoAndreas SchnappAnnette Schuler-Metz
    • Dennis FiegenSandra HandschuhSilke HobbieMatthias HoffmannTakeshi KonoYayoi SatoAndreas SchnappAnnette Schuler-Metz
    • A61K31/573A61K31/4375A61P11/00A61P19/10A61P1/04A61P31/14A61P7/06A61P25/00C07D471/04A61P19/02
    • C07D471/04C07D519/00
    • The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R1 can represent a group A selected from among the group comprising —O—R3, —NR3 R4, —CR3R4R5, -(ethyne)-R3, —S—R3, —SO—R3, and SO2—R3, or R1 represents a group B selected from among the group comprising: —C6-10-aryl;—a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom;—a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and—a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims 1, and R3,R4,R5,R6, and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.
    • 本发明涉及式1的新型取代萘啶以及其药理学上可接受的盐,非对映异构体,对映异构体,外消旋物,水合物或溶剂合物。 在式1中,R 1可以表示选自-O-R 3,-NR 3 R 4,-CR 3 R 4 R 5, - (乙炔)-R 3,-S-R 3,-SO-R 3和SO 2 -R 3的基团A, 或R 1表示选自包括以下基团的基团:-C 6-10 - 芳基; - 含有1至3个独立地选自以下的杂原子的五元至十元单环或双环杂芳基:N,O, 和S,其中所述杂芳基通过C原子或N原子连接到根据式1的结构; - 含有1至3个独立选择的杂原子的三元至十元单环或双环饱和或部分饱和的杂环 包括N,O和S的基团,其中所述杂环通过C原子或N原子连接到根据式1的结构; 和可以任选地含有1,2或3个独立地选自包括N,O和S的基团的杂原子的5元至11元螺环,其中所述螺环与根据式1的结构连接 通过C原子或N原子,其中所述基团B可以如权利要求1所述任选被取代,并且R 3,R 4,R 5,R 6和m可以具有权利要求1中所示的含义。本发明还涉及药物组合物 含有所述化合物。
    • 8. 发明授权
    • 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
    • 4-二甲基氨基 - 苯基取代的萘啶,及其用作药物
    • US08604049B2
    • 2013-12-10
    • US13057330
    • 2009-07-23
    • Dennis FiegenSandra HandschuhSilke HobbieMatthias HoffmannTakeshi KonoYayoi SatoAndreas SchnappAnnette Schuler-Metz
    • Dennis FiegenSandra HandschuhSilke HobbieMatthias HoffmannTakeshi KonoYayoi SatoAndreas SchnappAnnette Schuler-Metz
    • A61K31/573A61K31/4375A61P11/00A61P19/10A61P1/04A61P31/14A61P7/06A61P25/00A61P19/02C07D471/04
    • C07D471/04C07D519/00
    • The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R1 can represent a group A selected from among the group comprising —O—R3, —NR3R4, —CR3R4R5, -(ethyne)-R3, —S—R3, —SO—R3, and SO2—R3, or R1 represents a group B selected from among the group comprising: —C6-10-aryl; —a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom; —a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and —a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims 1, and R3, R4, R5, R6, and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.
    • 本发明涉及式1的新型取代萘啶以及其药理学上可接受的盐,非对映异构体,对映异构体,外消旋物,水合物或溶剂合物。 在式1中,R 1可以表示选自-O-R 3,-NR 3 R 4,-CR 3 R 4 R 5, - (乙炔)-R 3,-S-R 3,-SO-R 3和SO 2 -R 3的基团A,或 R 1表示选自以下的基团B:-C 6-10 - 芳基; 包含1至3个独立地选自N,O和S的杂原子的五元至十元单环或二环杂芳基,其中所述杂芳基通过C原子连接至根据式1的结构,或 一个N原子; 包含1-3个独立地选自包括N,O和S的杂原子的3至10元,单环或双环饱和或部分饱和的杂环,其中所述杂环与根据式1的结构连接 通过C原子或N原子; 和可以任选地含有1,2或3个独立地选自N,O和S的组的杂原子的5元至11元螺环,其中所述螺环与根据式1的结构连接 通过C原子或N原子,其中所述基团B可以如权利要求1所述任选被取代,并且R 3,R 4,R 5,R 6和m可以具有权利要求1中所示的含义。本发明还涉及药物组合物 含有所述化合物。